Coronary Stents Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update

Coronary Stents Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update


Summary

GlobalData's Medical Devices sector report, “Coronary Stents Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Coronary Stents pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

A stent is an expandable perforated tube that is inserted into a natural conduit of the body to prevent or counteract a disease-induced localized flow constriction.

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Coronary Stents under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Coronary Stents and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Coronary Stents under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


1 Table of Contents
1 About GlobalData
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
3.1 Coronary Stents Overview
4 Products under Development
4.1 Coronary Stents - Pipeline Products by Stage of Development
4.2 Coronary Stents - Pipeline Products by Segment
4.3 Coronary Stents - Pipeline Products by Territory
4.4 Coronary Stents - Pipeline Products by Regulatory Path
4.5 Coronary Stents - Pipeline Products by Estimated Approval Date
4.6 Coronary Stents - Ongoing Clinical Trials
5 Coronary Stents - Pipeline Products under Development by Companies
5.1 Coronary Stents Companies - Pipeline Products by Stage of Development
5.2 Coronary Stents – Companies Pipeline Products by Stage of Development
6 Coronary Stents Companies and Product Overview
6.1 Abbott Vascular Inc Company Overview
6.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
6.2 Adcomp Technologies Inc. Company Overview
6.2.1 Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
6.3 Advanced Bifurcation Systems Inc Company Overview
6.3.1 Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
6.4 Aeon Bioscience Company Overview
6.4.1 Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
6.5 Amaranth Medical Inc Company Overview
6.5.1 Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
6.6 Arterius Ltd Company Overview
6.6.1 Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.7 Atrium Medical Corp Company Overview
6.7.1 Atrium Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
6.8 Axordia Ltd (Inactive) Company Overview
6.8.1 Axordia Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
6.9 B. Braun Melsungen AG Company Overview
6.9.1 B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
6.1 Bactiguard Holding AB Company Overview
6.10.1 Bactiguard Holding AB Pipeline Products & Ongoing Clinical Trials Overview
6.11 Bionext Biotech Products Ltd. Company Overview
6.11.1 Bionext Biotech Products Ltd. Pipeline Products & Ongoing Clinical Trials Overview
6.12 Biosensors International Group Ltd Company Overview
6.12.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.13 Biosten, LLC Company Overview
6.13.1 Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
6.14 Biotronik AG Company Overview
6.14.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
6.15 Biotronik SE & Co KG Company Overview
6.15.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
6.16 Biotyx Medical (Shenzhen) Co Ltd Company Overview
6.16.1 Biotyx Medical (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.17 Boston Scientific Corp Company Overview
6.17.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
6.18 Cardionovum GmbH Company Overview
6.18.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
6.19 Cardiorev Pte Ltd (Inactive) Company Overview
6.19.1 Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
6.2 Columbia University Company Overview
6.20.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview
6.21 Concept Medical Inc Company Overview
6.21.1 Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
6.22 Contego Medical LLC Company Overview
6.22.1 Contego Medical LLC Pipeline Products & Ongoing Clinical Trials Overview
6.23 Cordis Corp Company Overview
6.23.1 Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
6.24 Cytograft Tissue Engineering Inc (Inactive) Company Overview
6.24.1 Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
6.25 DISA Vascular (Pty) Ltd Company Overview
6.25.1 DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.26 Elixir Medical Corp Company Overview
6.26.1 Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
6.27 Endomimetics LLC Company Overview
6.27.1 Endomimetics LLC Pipeline Products & Ongoing Clinical Trials Overview
6.28 Envision Scientific Pvt Ltd Company Overview
6.28.1 Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.29 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview
6.29.1 HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
6.3 I.B.S. S.p.A. Company Overview
6.30.1 I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview
6.31 Icon Interventional Systems, Inc. Company Overview
6.31.1 Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
6.32 ID Nest Medical SAS Company Overview
6.32.1 ID Nest Medical SAS Pipeline Products & Ongoing Clinical Trials Overview
6.33 InspireMD Inc Company Overview
6.33.1 InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
6.34 Intressa Vascular SA Company Overview
6.34.1 Intressa Vascular SA Pipeline Products & Ongoing Clinical Trials Overview
6.35 Japan Stent Technology Co., Ltd. Company Overview
6.35.1 Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
6.36 JW Medical Systems Ltd Company Overview
6.36.1 JW Medical Systems Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.37 Kaneka Corp Company Overview
6.37.1 Kaneka Corp Pipeline Products & Ongoing Clinical Trials Overview
6.38 Kyoto Medical Planning Co Ltd Company Overview
6.38.1 Kyoto Medical Planning Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.39 Lifetech Scientific (Shenzhen) Co Ltd Company Overview
6.39.1 Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.4 MangoGen Pharma Inc Company Overview
6.40.1 MangoGen Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
6.41 Manli Cardiology Ltd Company Overview
6.41.1 Manli Cardiology Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.42 Medinol Ltd Company Overview
6.42.1 Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.43 Medlogics Device Corp (Inactive) Company Overview
6.43.1 Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
6.44 Medtronic Plc Company Overview
6.44.1 Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview
6.45 Meril Life Sciences Pvt Ltd Company Overview
6.45.1 Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.46 Miami Cardiovascular Innovations Company Overview
6.46.1 Miami Cardiovascular Innovations Pipeline Products & Ongoing Clinical Trials Overview
6.47 Micell Technologies Inc Company Overview
6.47.1 Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
6.48 Michigan Technological University Company Overview
6.48.1 Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview
6.49 MicroPort Scientific Corp Company Overview
6.49.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
6.5 Minvasys SAS Company Overview
6.50.1 Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview
6.51 MIV Therapeutics Inc Company Overview
6.51.1 MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
6.52 NanoCoeur, Inc. Company Overview
6.52.1 NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview
6.53 Nanova, Inc Company Overview
6.53.1 Nanova, Inc Pipeline Products & Ongoing Clinical Trials Overview
6.54 Neovasc Inc Company Overview
6.54.1 Neovasc Inc Pipeline Products & Ongoing Clinical Trials Overview
6.55 Nesstent Ltd. Company Overview
6.55.1 Nesstent Ltd. Pipeline Products & Ongoing Clinical Trials Overview
6.56 Nexeon MedSystems Inc Company Overview
6.56.1 Nexeon MedSystems Inc Pipeline Products & Ongoing Clinical Trials Overview
6.57 North Carolina State University Company Overview
6.57.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
6.58 Northwestern University Company Overview
6.58.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
6.59 NuVascular Technologies Inc Company Overview
6.59.1 NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
6.6 OrbusNeich Company Overview
6.60.1 OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
6.61 Palmaz Scientific Inc (Inactive) Company Overview
6.61.1 Palmaz Scientific Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
6.62 Pediastent LLC Company Overview
6.62.1 Pediastent LLC Pipeline Products & Ongoing Clinical Trials Overview
6.63 QualiMed Innovative Medizinprodukte GmbH Company Overview
6.63.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
6.64 Qvanteq AG Company Overview
6.64.1 Qvanteq AG Pipeline Products & Ongoing Clinical Trials Overview
6.65 Relisys Medical Devices Ltd Company Overview
6.65.1 Relisys Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.66 REVA Medical Inc Company Overview
6.66.1 REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
6.67 Rontis AG Company Overview
6.67.1 Rontis AG Pipeline Products & Ongoing Clinical Trials Overview
6.68 S3V Vascular Technologies Company Overview
6.68.1 S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview
6.69 Sahajanand Medical Technologies Pvt Ltd Company Overview
6.69.1 Sahajanand Medical Technologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.7 Shandong Rientech Medical Tech Co Ltd Company Overview
6.70.1 Shandong Rientech Medical Tech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.71 Shanghai Bio-heart Biological Technology Co Ltd Company Overview
6.71.1 Shanghai Bio-heart Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.72 Shanghai BIOMAGIC Medical Device Co Ltd Company Overview
6.72.1 Shanghai BIOMAGIC Medical Device Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.73 Shanghai Healing Medical Instruments Co Ltd Company Overview
6.73.1 Shanghai Healing Medical Instruments Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.74 Shanghai MicroPort Medical Group Co Ltd Company Overview
6.74.1 Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.75 Shanghai MicroPort Rhythm MedTech Co Ltd Company Overview
6.75.1 Shanghai MicroPort Rhythm MedTech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.76 Sino Medical Sciences Technology Inc Company Overview
6.76.1 Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview
6.77 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview
6.77.1 Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview
6.78 Stentys SA Company Overview
6.78.1 Stentys SA Pipeline Products & Ongoing Clinical Trials Overview
6.79 Svelte Medical Systems Inc Company Overview
6.79.1 Svelte Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
6.8 Tepha Inc Company Overview
6.80.1 Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview
6.81 Terumo Corp Company Overview
6.81.1 Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview
6.82 Terumo Interventional Systems Company Overview
6.82.1 Terumo Interventional Systems Pipeline Products & Ongoing Clinical Trials Overview
6.83 TissueGen Inc Company Overview
6.83.1 TissueGen Inc Pipeline Products & Ongoing Clinical Trials Overview
6.84 Translumina Therapeutics LLP Company Overview
6.84.1 Translumina Therapeutics LLP Pipeline Products & Ongoing Clinical Trials Overview
6.85 Tremedics Medical Devices LLC Company Overview
6.85.1 Tremedics Medical Devices LLC Pipeline Products & Ongoing Clinical Trials Overview
6.86 TrendyMED Inc. Company Overview
6.86.1 TrendyMED Inc. Pipeline Products & Ongoing Clinical Trials Overview
6.87 UAB Minority Health and Health Equity Research Center Company Overview
6.87.1 UAB Minority Health and Health Equity Research Center Pipeline Products & Ongoing Clinical Trials Overview
6.88 University of Colorado Company Overview
6.88.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview
6.89 University of Florida Company Overview
6.89.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview
6.9 University of Galway Company Overview
6.90.1 University of Galway Pipeline Products & Ongoing Clinical Trials Overview
6.91 University of Michigan Company Overview
6.91.1 University of Michigan Pipeline Products & Ongoing Clinical Trials Overview
6.92 University of Strathclyde Company Overview
6.92.1 University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
6.93 University of Utah Company Overview
6.93.1 University of Utah Pipeline Products & Ongoing Clinical Trials Overview
6.94 VasoTech Inc. Company Overview
6.94.1 VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
6.95 Viller Scientific LLC Company Overview
6.95.1 Viller Scientific LLC Pipeline Products & Ongoing Clinical Trials Overview
6.96 Vornia Biomaterials Ltd Company Overview
6.96.1 Vornia Biomaterials Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.97 Xenogenics Corporation Company Overview
6.97.1 Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview
7 Coronary Stents- Recent Developments
7.1 Apr 12, 2023: Medtronic has a layoff in California
7.2 Apr 06, 2023: Merit Medical Systems to Announce First Quarter 2023 Results on April 26, 2023
7.3 Mar 16, 2023: Medtronic joins in $25M funding round for home monitoring company
7.4 Mar 08, 2023: OrbusNeich Announces Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million
7.5 Feb 22, 2023: ICON Reports Fourth Quarter and Full Year 2022 Results
7.6 Feb 14, 2023: Asahi Intecc Announces Consolidated Financial Results for the Six Months Ended December 31, 2022
7.7 Feb 09, 2023: Terumo Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023
7.8 Feb 09, 2023: Terumo Corp Announces Consolidated Financial Results for the Third Quarter Ended December 31, 2022
7.9 Feb 06, 2023: Surmodics Lays off 58 employees
7.1 Feb 06, 2023: Surmodics Reports First Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
7.11 Feb 03, 2023: Merit Medical Systems to Announce Fourth Quarter and Year End 2022 Results and Issue Fiscal Year 2023 Guidance on February 22, 2023
7.12 Jan 31, 2023: Surmodics to Host Virtual Annual Meeting of Shareholders
7.13 Dec 08, 2022: Edwards Lifesciences Announces CEO Succession Plan
7.14 Dec 07, 2022: Cook Medical welcomes Dr. John A. Kaufman as Chief Medical Officer
7.15 Dec 06, 2022: Potrero Medical to Present at Jefferies Virtual Private MedTech Summit
7.16 Nov 23, 2022: Medtronic Reports Quarterly Earnings
7.17 Nov 22, 2022: Medtronic reports second quarter fiscal 2023 financial results
7.18 Nov 15, 2022: Medtronic Set to Announce Earnings on Tuesday
7.19 Nov 11, 2022: Asahi Intecc Consolidated Financial Results for the Three Months Ended September 30, 2022
7.2 Nov 10, 2022: Terumo Corp Announces Consolidated Financial Results for the Second Quarter Ended September 30, 2022
7.21 Oct 20, 2022: Edwards Lifesciences to Host Earnings Conference Call on October 27, 2022
7.22 Oct 13, 2022: Merit Medical Systems to Announce Third Quarter Results on October 26, 2022
7.23 Sep 07, 2022: Medtronic to appear at September investor conferences
7.24 Aug 23, 2022: Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022
7.25 Aug 23, 2022: Medtronic reports first quarter fiscal 2023 financial results
7.26 Aug 23, 2022: Medtronic Announces Quarterly Earnings Results
7.27 Aug 16, 2022: Boston Scientific Announces Upcoming Conference Schedule
7.28 Jul 28, 2022: Quantum Healthcare Announces Appointment Of Independent Director
7.29 Jul 27, 2022: ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
7.3 Jul 27, 2022: Merit Medical Reports Results for Quarter Ended June 30, 2022
7.31 Jul 21, 2022: Edwards Lifesciences to Host Earnings Conference Call on July 28, 2022
7.32 Jul 20, 2022: Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance
7.33 Jul 14, 2022: Merit Medical Systems to Announce Second Quarter Results on July 27, 2022
7.34 Jul 08, 2022: Cordis Names Bryan Loo President of Asia-pacific Region
7.35 Jul 01, 2022: Osprey Medical : Business restructure
7.36 Jun 27, 2022: Medtronic Board appoints Lidia Fonseca as a new director
7.37 May 27, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results
7.38 May 26, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results announces 8% dividend increase
7.39 May 23, 2022: Edwards Lifesciences to Present at the Bernstein 38th Annual Strategic Decisions Conference
8 Appendix
8.1 Methodology
8.2 About GlobalData
8.3 Contact Us
8.4 Disclaimer
1.1 List of Tables
Table 1: Coronary Stents - Pipeline Products by Stage of Development
Table 2: Coronary Stents - Pipeline Products by Segment
Table 3: Coronary Stents - Pipeline Products by Territory
Table 4: Coronary Stents - Pipeline Products by Regulatory Path
Table 5: Coronary Stents - Pipeline Products by Estimated Approval Date
Table 6: Coronary Stents - Ongoing Clinical Trials
Table 7: Coronary Stents Companies - Pipeline Products by Stage of Development
Table 8: Coronary Stents – Companies Pipeline Products by Stage of Development
Table 9: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 10: Second Generation Bioresorbable Vascular Scaffold - Product Status
Table 11: Second Generation Bioresorbable Vascular Scaffold - Product Description
Table 12: XIENCE BIOPRIME - Product Status
Table 13: XIENCE BIOPRIME - Product Description
Table 14: Xience Max - Product Status
Table 15: Xience Max - Product Description
Table 16: Xience SBA Everolimus Eluting Coronary Stent System - Product Status
Table 17: Xience SBA Everolimus Eluting Coronary Stent System - Product Description
Table 18: XIENCE Thinman DES - Product Status
Table 19: XIENCE Thinman DES - Product Description
Table 20: ZoMaxx Drug Eluting Coronary Stent System - Product Status
Table 21: ZoMaxx Drug Eluting Coronary Stent System - Product Description
Table 22: Abbott Vascular Inc - Ongoing Clinical Trials Overview
Table 23: Xience SBA Everolimus Eluting Coronary Stent System - A Multi-center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries: CRYSTAL Study
Table 24: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective, Multi-center, Single-blinded, Randomized Trial of the Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System in Patients with Coronary Artery Disease: IRONMAN-II
Table 25: Xience SBA Everolimus Eluting Coronary Stent System - Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5
Table 26: Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 27: Dual Drug Eluting Stent - Product Status
Table 28: Dual Drug Eluting Stent - Product Description
Table 29: Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 30: ABS Stenting System - Drug Eluting Stent - Product Status
Table 31: ABS Stenting System - Drug Eluting Stent - Product Description
Table 32: Stenting System - Bare Metal Stent - Product Status
Table 33: Stenting System - Bare Metal Stent - Product Description
Table 34: Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Drug Eluting Stent - Product Status(Aeon Bioscience)
Table 36: Drug Eluting Stent - Product Description(Aeon Bioscience)
Table 37: Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 38: -micron MAGNITUDE Bioresorbable Scaffold - Product Status
Table 39: -micron MAGNITUDE Bioresorbable Scaffold - Product Description
Table 40: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
Table 41: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
Table 42: DEFIANCE Scaffold - Product Status
Table 43: DEFIANCE Scaffold - Product Description
Table 44: FORTITUDE Scaffold - Product Status
Table 45: FORTITUDE Scaffold - Product Description
Table 46: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
Table 47: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
Table 48: Second Generation FORTITUDE Scaffold - Product Status
Table 49: Second Generation FORTITUDE Scaffold - Product Description
Table 50: Amaranth Medical Inc - Ongoing Clinical Trials Overview
Table 51: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II
Table 52: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III
Table 53: Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 54: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status
Table 55: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description
Table 56: Atrium Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 57: Next Generation Super Flexible Cobalt Chromium Coronary Stent - Product Status
Table 58: Next Generation Super Flexible Cobalt Chromium Coronary Stent - Product Description
Table 59: Axordia Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 60: Regenerative Stent - Product Status
Table 61: Regenerative Stent - Product Description
Table 62: B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
Table 63: Coroflex DEBlue - Product Status
Table 64: Coroflex DEBlue - Product Description
Table 65: Bactiguard Holding AB Pipeline Products & Ongoing Clinical Trials Overview
Table 66: Metal-Coated Vascular Stent - Product Status
Table 67: Metal-Coated Vascular Stent - Product Description
Table 68: Bionext Biotech Products Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 69: Biostent - Product Status
Table 70: Biostent - Product Description
Table 71: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 72: BioFreedom Ultra - Product Status
Table 73: BioFreedom Ultra - Product Description
Table 74: Sparrow Drug Eluting Stent System - Product Status
Table 75: Sparrow Drug Eluting Stent System - Product Description
Table 76: Biosensors International Group Ltd - Ongoing Clinical Trials Overview
Table 77: BioFreedom Ultra - A Pilot Study Registry of the BioFreedom BA9 Ultra Drug-Coated Coronary Stent for Patients With ST Elevation Myocardial Infarct (STEMI) Undergoing Percutaneous Coronary Intervention (PCI)
Table 78: BioFreedom Ultra - A Post-Market Registry of the BioFreedom Ultra CoCr Biolimus A9 Coated Coronary Stent System
Table 79: BioFreedom Ultra - A Prospective Multicenter Single Arm Trial to Assess the Safety and Effectiveness of Additional Sizes of the BioFreedom Ultra CoCr Biolimus A9 Coated Coronary Stent System
Table 80: BioFreedom Ultra - A Prospective Study of the BioFreedom Biolimus A9 Drug Coated Stent in Patients at High Risk for Bleeding
Table 81: BioFreedom Ultra - A Randomized Controlled Comparison Between One Versus More than Six Months of Dual Antiplatelet Therapy after Biolimus A9-eluting Stent Implantation
Table 82: BioFreedom Ultra - Asian Registry of the BioFreedom BA9 Drug-Coated Coronary Stent for Patients with ST Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI)
Table 83: BioFreedom Ultra - BioFreedom Ultra Stent in Hong Kong All Comers Registry
Table 84: BioFreedom Ultra - Comparison of Polymer-free Cobalt-Chromium Thin Drug-coated Stents with Biodegradable Polymer Ultrathin Sirolimus-Eluting Stents and Prasugrel Monotherapy with Conventional 12-Month Dual Antiplatelet Therapy
Table 85: BioFreedom Ultra - Evaluation of Effectiveness and Safety of Biofreedom Family Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Table 86: BioFreedom Ultra - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
Table 87: BioFreedom Ultra - P2Y12 Inhibitor-based Single Antiplatelet Therapy Versus Conventional Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With BioFreedom Ultra Drug-coated Stent for Unprotected Left Main Coronary Artery Disease (ULTRA-LM)
Table 88: BioFreedom Ultra - Randomized Comparison of a Polymer-free Biolimus-eluting BioFreedom Stent with a Biodegradable-polymer Sirolimus-eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention
Table 89: BioFreedom Ultra - Randomized Comparison of Vascular Healing of a Polymer-free Biolimus-eluting BIOFREEDOM Stent with a Biodegradable-polymer Sirolimus-eluting ORSIRO Stent in Patients with ST-segment Elevation Myocardial Infarction 6
Table 90: Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 91: Biodegradable Endovascular Implant - Product Status
Table 92: Biodegradable Endovascular Implant - Product Description
Table 93: Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
Table 94: Coronary Stent System - Product Status
Table 95: Coronary Stent System - Product Description
Table 96: DREAMS 3G System - Product Status
Table 97: DREAMS 3G System - Product Description
Table 98: Magmaris Bioresorbable Magnesium Scaffold - Product Status
Table 99: Magmaris Bioresorbable Magnesium Scaffold - Product Description
Table 100: Biotronik AG - Ongoing Clinical Trials Overview
Table 101: Magmaris Bioresorbable Magnesium Scaffold - A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions: The BIFSORB Pilot Study II
Table 102: Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II
Table 103: Magmaris Bioresorbable Magnesium Scaffold - Biotroniks - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV
Table 104: Magmaris Bioresorbable Magnesium Scaffold - Coronary Artery Healing Process after Bioresorbable Scaffold in Patients with Non-ST-segment Elevation Myocardial Infarction (NSTEMI)
Table 105: Magmaris Bioresorbable Magnesium Scaffold - Optical Coherence Guided Treatment of ST-segment Elevation Myocardial Infarction with the Drug-eluting Resorbable Magnesium Scaffold: The BEST- MAG Multicentre Study (Belgian ST-segment Elevation Myocardial Infarction Treatment with Resorbable Magnesium Scaffold)
Table 106: Magmaris Bioresorbable Magnesium Scaffold - Retrospective, Observational Register to Investigate the Procedural and Post Procedural Implantation of Bioabsorbable Magnesium Scaffolds Magmaris (MAGIC Registry)
Table 107: Magmaris Bioresorbable Magnesium Scaffold - RMS (Resorbable Magnesium Scaffolds) Registry
Table 108: Magmaris Bioresorbable Magnesium Scaffold - Scaffold Implantation in Emilia-Romagna
Table 109: DREAMS 3G System - BIOTRONIK - Safety and Clinical Performance of the - Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries
Table 110: DREAMS 3G System - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A Randomized Controlled Trial
Table 111: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 6
Table 112: AMS-2 - Product Status 6
Table 113: AMS-2 - Product Description 6
Table 114: ProGenic Pimecrolimus-eluting Coronary Stent System - Product Status 7
Table 115: ProGenic Pimecrolimus-eluting Coronary Stent System - Product Description 7
Table 116: Biotyx Medical (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 117: IBS Angel - Product Status
Table 118: IBS Angel - Product Description
Table 119: Biotyx Medical (Shenzhen) Co Ltd - Ongoing Clinical Trials Overview
Table 120: IBS Angel - A Prospective, Multi-center, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of Iron Bioresorbable Scaffold System (IBS Angel) in Patients with Pulmonary Artery Stenosis
Table 121: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 122: Fully Resorbable Drug-Eluting Scaffold System - Product Status
Table 123: Fully Resorbable Drug-Eluting Scaffold System - Product Description
Table 124: JACTAX Drug Eluting Stent - Product Status
Table 125: JACTAX Drug Eluting Stent - Product Description
Table 126: SYNERGY - High Bleeding Risk - Product Status
Table 127: SYNERGY - High Bleeding Risk - Product Description
Table 128: SYNERGY 48 Stent - Product Status
Table 129: SYNERGY 48 Stent - Product Description
Table 130: SYNERGY XD Stent - Product Status
Table 131: SYNERGY XD Stent - Product Description
Tabl

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings